Literature DB >> 189132

Acceleration and weakness in parkinsonian dysarthria.

R Netsell, B Daniel, G G Celesia.   

Abstract

This report presents some of the underlying neuromuscular mechanisms of dysarthric speech production as they are manifested in selected individuals with parkinsonism. Earlier explanations of parkinsonian dysarthria emphasized that the balanced hypertonus of rigidity formed the basis of reduced range of movements in speech. The present data reveal two problems in the neuromuscular control signals that can result in a reduced range of speech movements in the absence of rigidity. These neuromuscular problems are described as acceleration and weakness. The implication of these findings for the evaluation and treatment of parkinsonian dysarthria is discussed.

Entities:  

Mesh:

Year:  1975        PMID: 189132     DOI: 10.1044/jshd.4002.170

Source DB:  PubMed          Journal:  J Speech Hear Disord        ISSN: 0022-4677


  5 in total

1.  Basic parameters of articulatory movements and acoustics in individuals with Parkinson's disease.

Authors:  Bridget Walsh; Anne Smith
Journal:  Mov Disord       Date:  2012-01-04       Impact factor: 10.338

2.  Kinematic Features of Jaw and Lips Distinguish Symptomatic From Presymptomatic Stages of Bulbar Decline in Amyotrophic Lateral Sclerosis.

Authors:  Andrea Bandini; Jordan R Green; Jun Wang; Thomas F Campbell; Lorne Zinman; Yana Yunusova
Journal:  J Speech Lang Hear Res       Date:  2018-05-17       Impact factor: 2.297

3.  Short- and long-term dopaminergic effects on dysarthria in early Parkinson's disease.

Authors:  Sabine Skodda; Wenke Visser; Uwe Schlegel
Journal:  J Neural Transm (Vienna)       Date:  2009-12-12       Impact factor: 3.575

4.  Aerodynamic assessment of phonatory onset in Parkinson's disease: evidence of decreased scaling of laryngeal and respiratory control.

Authors:  Michael J Hammer
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

5.  Hypernasality associated with basal ganglia dysfunction: evidence from Parkinson's disease and Huntington's disease.

Authors:  Michal Novotný; Jan Rusz; Roman Čmejla; Hana Růžičková; Jiří Klempíř; Evžen Růžička
Journal:  PeerJ       Date:  2016-09-29       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.